Advertisement

Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma

  • Amy Lewis Hennessy
  • Alan L. Robin
Chapter

Abstract

The medical management of glaucoma is often compromised by patients’ nonadherence with prescribed topical therapy - both the ability to execute eye drop administration and persistency of medication use. This can be made more complex in patients who are taking multiple systemic medi­cations and multiple medications to lower IOP. The consequence of inadequate treatment arising from patient nonadherence is disease progression, with permanent and irreversible loss of visual function. The Early Manifest Glaucoma Treatment Study (EMGTS) found that among individuals treated and closely monitored for their glaucoma, 57% progressed in a 5-year period. In 2008, Urquhart described noncompliance, nonabsorption, and nonresponse as possibilities for disease progression despite use of prescribed medications. It may be that part of the reason for progression in glaucoma is poor adherence to prescribed therapy.

Keywords

Diabetic Macular Edema Proliferative Diabetic Retinopathy Ocular Hypertension Trabecular Meshwork Central Retinal Vein Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2:1031–1033.CrossRefPubMedGoogle Scholar
  2. 2.
    Norell S. Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma. Acta Ophthalmol Suppl (Copenh). 1980;143:1–28.Google Scholar
  3. 3.
    Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol. 1980;64:134–141.CrossRefGoogle Scholar
  4. 4.
    Norell SE, Granstrom PA, Wassen R. A medication monitor and fluorescein technique designed to study medication behaviour. Acta Ophthalmol (Copenh). 1980;58:459–467.CrossRefGoogle Scholar
  5. 5.
    Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524–530.PubMedGoogle Scholar
  6. 6.
    Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523.PubMedGoogle Scholar
  7. 7.
    Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–480.CrossRefPubMedGoogle Scholar
  8. 8.
    Kholdebarin R, Campbell RJ, Jin Y, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–461.CrossRefPubMedGoogle Scholar
  9. 9.
    Brown M, Brown G, Spaeth G. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol. 1984;19(1):2–5.PubMedGoogle Scholar
  10. 10.
    Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052–5057.CrossRefPubMedGoogle Scholar
  11. 11.
    Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114:648–652.CrossRefPubMedGoogle Scholar
  12. 12.
    Robin AL, Novack GD, Covert DW, Crockett S, Marcic T. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540.CrossRefPubMedGoogle Scholar
  13. 13.
    Robin AL, Stone JL, Sleath B, Covert DW, Cagle GD. An Objective Evaluation in Glaucoma Patients of Eye-Drop Instillation Using Video Observations and Patient Surveys. Abstract presented at American Glaucoma Society Annual meeting, Washington DC, March 2008.Google Scholar
  14. 14.
    Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–398.CrossRefPubMedGoogle Scholar
  15. 15.
    Nordstrom BL, Friedman DS, Mozafarri E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.PubMedGoogle Scholar
  16. 16.
    Covert D, Robin AL, Novack GD. Letter to the editor. Systemic medications and glaucoma patients. Ophthalmology. 2005;112(10):1849–1850.CrossRefPubMedGoogle Scholar
  17. 17.
    Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971–976.CrossRefPubMedGoogle Scholar
  18. 18.
    Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–868.CrossRefPubMedGoogle Scholar
  19. 19.
    Patel SC, Spaeth G. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 2005;26(3):233–236.Google Scholar
  20. 20.
    Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.CrossRefPubMedGoogle Scholar
  21. 21.
    Urquhart J. The drugs not taken. Science. 2008;321(5890):769.CrossRefPubMedGoogle Scholar
  22. 22.
    Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.CrossRefPubMedGoogle Scholar
  23. 23.
    Tsai T, Robin AL, Smith JP. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29–35.PubMedGoogle Scholar
  24. 24.
    O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836–837.CrossRefPubMedGoogle Scholar
  25. 25.
    Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915–922.PubMedGoogle Scholar
  26. 26.
    Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899.CrossRefPubMedGoogle Scholar
  27. 27.
    Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990;97:1423–1427.PubMedGoogle Scholar
  28. 28.
    Augustin AJ, D’Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):9–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Augustin A. Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237–246.CrossRefPubMedGoogle Scholar
  30. 30.
    Russell SR, Hudson HL, Jerdan JA, Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration - a review of clinical outcomes. Surv Ophthalmol. 2007;52(suppl 1):S79-S90.CrossRefPubMedGoogle Scholar
  31. 31.
    Clark AF, Wilson K, deKater AW, Allingham RR, McCartney MD. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995;36:478–489.PubMedGoogle Scholar
  32. 32.
    Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783–793.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2): 275–284.CrossRefPubMedGoogle Scholar
  34. 34.
    Robin AL, Clark AF, Covert D, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Prata TS, Tavares IM, Mello PAA, Tamura CY, Belfort R Jr. Anterior juxtascleral depot of anecortave acetate: intraocular pressure reduction in different types of glaucoma. Association for Research in Vision and Ophthalmology (ARVO); abstract 2008 E-1205, poster A47.Google Scholar
  36. 36.
    Callanan D, Fuller C, Landry TA, Dickerson JE, Bergamini MVW. Prophylactic anecortave acetate in patients with a retisert implant. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 2008 E-5630.Google Scholar
  37. 37.
    Landry TA, Dickerson J, Merriam JC. The use of anecortave acetate for refractory, complex glaucoma. Association for Research in Vision and Ophthalmology (ARVO) 2008; abstract 1206/A48.Google Scholar
  38. 38.
    Robin AL, Suan EP, Sjaarda RN, Callanan DG, DeFaller J. Anecortave acetate lowers intraocular pressure in eyes with steroid injection-related glaucoma. Arch Ophthalmol. 2009;127:173–178.CrossRefPubMedGoogle Scholar
  39. 39.
    Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24–27.CrossRefPubMedGoogle Scholar
  40. 40.
    Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593–598.CrossRefPubMedGoogle Scholar
  41. 41.
    Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26(4):277–281.CrossRefPubMedGoogle Scholar
  42. 42.
    Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053–1060.PubMedGoogle Scholar
  43. 43.
    Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103(4):650–656.PubMedGoogle Scholar
  44. 44.
    Solomon A, Ticho U, Frucht-Pery J. Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. J Ocul Pharmacol Ther. 1999;15(4):283–293.CrossRefPubMedGoogle Scholar
  45. 45.
    DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297–300.PubMedGoogle Scholar
  46. 46.
    Ashkenazi I, Melamed S, Avni I, Bartov E, Blumenthal M. Risk factors associated with late infection of filtering blebs and endophthalmitis. Ophthalmic Surg. 1991;22(10):570–574.PubMedGoogle Scholar
  47. 47.
    Phillips WB 2nd, Wong TP, Bergren RL, Friedberg MA, Benson WE. Late onset endophthalmitis associated with filtering blebs. Ophthalmic Surg. 1994;25(2):88–91.PubMedGoogle Scholar
  48. 48.
    Poulsen EJ, Allingham RR. Characteristics and risk factors of infections after glaucoma filtering surgery. J Glaucoma. 2000;9(6):438–443.PubMedGoogle Scholar
  49. 49.
    Clark AF. Steroids, ocular hypertension, and glaucoma. J Glaucoma. 1995;4:354–369.PubMedGoogle Scholar
  50. 50.
    Gottanka J, Chan D, Eichhorn M, Lutjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in persued human eyes. Invest Ophthalmol Vis Sci. 2004;45:153–158.CrossRefPubMedGoogle Scholar
  51. 51.
    Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in the human trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci. 2006;47:226–234.CrossRefPubMedGoogle Scholar
  52. 52.
    Clark AF, Millar C, Pang I-H, Jacobson N, Shepard AR. Adenoviral gene transfer of active human transforming growth factor-b2 induces elevated intraocular pressure in rats. 2006 Annual Meeting Association for Research in Vision and Ophthalmology. Abstract 4771.Google Scholar
  53. 53.
    Shepard AR, Millar JC, Pang IH, Jacobson N, Clark AF. Adenoviral gene transfer of active human transforming factor-b2 elevates intraocular pressure and reduces outflow facility in rodent eyes. In press.Google Scholar
  54. 54.
    Fleenor DL, Pang I-H, Clark AF. Regulation of PAI-1 protein in human trabecular meshwork cells. 2008 Annual Meeting Association for Research in Vision and Ophthalmology (ARVO), Abstract 1631.Google Scholar
  55. 55.
    Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67(9):1937–1944.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Amy Lewis Hennessy
    • 1
    • 2
  • Alan L. Robin
    • 3
  1. 1.International Health, Johns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Department of Ophthalmology/GlaucomaGreater Baltimore Medical CenterBaltimoreUSA
  3. 3.International Health, Bloomberg School of Public Health, Wilmer Institute, Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations